FTLF: FitLife Brands, Inc. Stock

by  •  • Comments Off on FTLF: FitLife Brands, Inc. Stock

SIC 2833 – Medicinal Chemicals and Botanical Products

Valuation
Market Cap ($M) 128.02
Enterprise Value ($M) 137.52
Book Value ($M) 34.16
Book Value / Share 3.71
Price / Book 3.75
NCAV ($M) -6.33
NCAV / Share -0.69
Price / NCAV -20.22

Profitability (mra)
Return on Invested Capital (ROIC) 0.17
Return on Assets (ROA) 0.15
Return on Equity (ROE) 0.31

Liquidity (mrq)
Quick Ratio 0.64
Current Ratio 1.50

Balance Sheet (mrq) ($M)
Current Assets 18.10
Assets 58.59
Liabilities 24.43
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-17 13G Askeladden Capital Management Llc 5.10

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-04-22 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPO
2024-03-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-13 1,425 18,806 7.58
2025-03-12 847 9,379 9.03
2025-03-11 1,650 28,042 5.88
2025-03-10 5,223 36,209 14.42

(click for more detail)

Similar Companies
FBRX – Forte Biosciences, Inc. FENC – Fennec Pharmaceuticals Inc.
FLGC – Flora Growth Corp. GALT – Galectin Therapeutics Inc.
GDTC – CytoMed Therapeutics Limited


Financial data and stock pages provided by
Fintel.io